Annex A 
 
 
   
   
   
   
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
MA (EU) number 
(Invented) 
name 
Strength 
Pharmaceutical 
Form 
Route of 
Administration 
Immediate 
Packaging 
Content 
(concentration) 
Pack size 
EU/1/17/1203/001 
EU/1/17/1203/002 
EU/1/17/1203/003 
EU/1/17/1203/004 
EU/1/17/1203/005 
EU/1/17/1203/006 
EU/1/17/1203/007 
EU/1/17/1203/008 
Insulin lispro 
Sanofi 
Insulin lispro 
Sanofi 
Insulin lispro 
Sanofi  
Insulin lispro 
Sanofi  
Insulin lispro 
Sanofi  
Insulin lispro 
Sanofi 
Insulin lispro 
Sanofi 
Insulin lispro 
Sanofi 
100 U/ml 
100 U/ml 
100 U/ml 
100 U/ml 
100 U/ml 
100 U/ml 
100 U/ml 
100 U/ml 
Solution for 
injection 
Solution for 
injection 
Solution for 
injection 
Solution for 
injection 
Solution for 
injection 
Solution for 
injection 
Solution for 
injection 
Solution for 
injection 
Intravenous use, 
Subcutaneous use 
Intravenous use, 
Subcutaneous use 
Intravenous use, 
Subcutaneous use 
Intravenous use, 
Subcutaneous use 
Intravenous use, 
Subcutaneous use 
Intravenous use, 
Subcutaneous use 
Intravenous use, 
Subcutaneous use 
Intravenous use, 
Subcutaneous use 
cartridge (glass)  3 ml (3.5mg/ml) 
5 cartridges 
cartridge (glass)  3 ml (3.5mg/ml) 
10 cartridges 
cartridge (glass) 
in pre-filled pen 
(SoloStar) 
cartridge (glass) 
in pre-filled pen 
(SoloStar) 
cartridge (glass) 
in pre-filled pen 
(SoloStar) 
cartridge (glass) 
in pre-filled pen 
(SoloStar) 
vial (glass) 
3 ml (3.5mg/ml) 
1 pre-filled pen 
3 ml (3.5mg/ml) 
3 pre-filled pens 
3 ml (3.5mg/ml) 
5 pre-filled pens 
3 ml (3.5mg/ml) 
10 pre-filled pens 
10 ml (3.5mg/ml) 
1 vial 
vial (glass) 
10 ml (3.5mg/ml) 
5 vials 
 
 
 
 
 
 
 
 
